Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

IRM Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma

Coordinator
Fundacion Para La Investigacion De Malaga En Biomedicina Y Salud, Spain
Runs
1 September 2027 to 31 August 2029
Status
Running
EU funding
€210k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101279225

What the project is doing

In the project's own words, from its summary on CORDIS.

Hepatocellular carcinoma (HCC), the most common primary liver cancer, has survival rates below 20%. Type 2 diabetes (T2D) markedly increases HCC incidence by driving metabolic and inflammatory changes, but the underlying mechanisms are unclear. Emerging evidence points to altered glutamine metabolism via the glutaminase isoenzymes GLS and GLS2 as a key link, though its role in diabetes-driven HCC remains unexplored. This project aims to elucidate how GLS and GLS2 regulate tumor bioenergetics, metabolic flexibility, and immune evasion in T2D-associated HCC, and to assess whether targeting these isoenzymes offers a viable therapeutic approach.

The specific aims are: 1) Characterize the roles of GLS and GLS2 in tumorigenesis and metabolic reprogramming in diabetes-associated HCC using CD-HFD mouse models.2) Dissect the distinct roles of GLS and GLS2 in regulating tumor bioenergetics and metabolic reprogramming in HCC to be used as targets in liver cancer.3) Design a therapeutic strategy for diabetes-driven HCC including GLS and GLS2 through their impact in the tumor microenvironment, focusing on immune cell infiltration, activation status of both isoenzymes, and their immunosuppressive mechanisms.

To achieve these goals, the study will employ physiologically relevant mouse models of metabolic syndrome–driven HCC, complemented by advanced methodologies including Seahorse metabolic flux assays, live-cell imaging, metabolomics, and single-cell RNA sequencing to dissect tumor–stromal–immune interactions. Sex-specific differences will also be systematically investigated. The project will generate new mechanistic insights into the metabolic crosstalk between diabetes and liver cancer, uncovering therapeutic vulnerabilities that target glutamine dependence while overcoming tumor heterogeneity and resistance.

Expected outcomes include the rational design of combinatorial therapies tailored to metabolic disease–associated HCC.

Topics

Who is involved

OrganisationCityCountryRole
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI